<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01259284</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0591</org_study_id>
    <nct_id>NCT01259284</nct_id>
  </id_info>
  <brief_title>Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer</brief_title>
  <official_title>A Double Blinded, Randomized Study Comparing the Effectiveness of Fish Oil Supplements, Oral Statins, and Placebo in Reducing the Incidence of Atrial Fibrillation Following a Lung Resection in Patients With Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if Lipitor (atorvastatin) or fish oil&#xD;
      supplements can help to control side effects of the heart that are commonly seen after lung&#xD;
      surgery (such as irregular heartbeat). Researchers also want to learn if one of these drugs&#xD;
      is more effective than the other at controlling side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:&#xD;
&#xD;
      Atorvastatin is designed to lower cholesterol by blocking its production in the liver. This&#xD;
      may help to decrease the chances of having a heart attack or a stroke.&#xD;
&#xD;
      Fish oil supplements are designed to lower fat levels in the blood by blocking their&#xD;
      production in the liver. This may help to decrease the chances of having a heart attack or a&#xD;
      stroke.&#xD;
&#xD;
      Atorvastatin is FDA-approved and commercially available for lowering cholesterol or fat&#xD;
      levels in the blood. Fish oil supplements are also commercially available.&#xD;
&#xD;
      Researchers want to compare the anti-inflammatory effects of Atorvastatin and fish oil&#xD;
      supplements.&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be assigned to a study&#xD;
      &quot;Part&quot; based on when you join this study. Up to 132 participants will be enrolled in Part 1&#xD;
      of the study. Up to 120 participants will be enrolled in Part 2 of the study.&#xD;
&#xD;
      If you are enrolled in Part 1, you will be randomly assigned (as in a roll of dice) to 1 of 3&#xD;
      groups. You will be provided with enough unmarked capsules for fourteen days plus a test&#xD;
      dose. You will take the test dose in the clinic in the presence of the research nurse.&#xD;
      Beginning 5 days before lung surgery (Day -5), you will take 1 capsule in the morning, as&#xD;
      well as 3 capsules 2 time each day (a total of 7 unmarked capsules each day) for 5 days. The&#xD;
      capsules should be taken with a cup (8 ounces) of water and may be taken with or without&#xD;
      food. You will be reminded by the research nurse to bring the remaining capsules from home&#xD;
      prior to your admission for surgery.&#xD;
&#xD;
        -  If you are in Group 1, the capsules you will take will be fish oil supplements and&#xD;
           placebo. A placebo is a substance that looks like the study drug but has no active&#xD;
           ingredients.&#xD;
&#xD;
        -  If you are in Group 2, the capsules you will take will be atorvastatin and placebo.&#xD;
&#xD;
        -  If you are in Group 3, the capsules you will take will be placebo only.&#xD;
&#xD;
      You will have an equal chance of being assigned to each group. Neither you nor the study&#xD;
      staff will know if you are receiving the study drug or the placebo. However, if needed for&#xD;
      your safety, the study staff will be able to find out what you are receiving.&#xD;
&#xD;
      After Part 1 is complete, the groups will be compared to learn if any group was more&#xD;
      effective than the others. If neither fish oil supplements nor atorvastatin is shown to be&#xD;
      more effective than the placebo, the study will be stopped. If fish oil or atorvastatin is&#xD;
      found to be more effective than the placebo, the study will continue to Part 2.&#xD;
&#xD;
      If you are enrolled in Part 2, you will be randomly assigned to 1 of 2 study groups. You will&#xD;
      be provided with enough unmarked capsules for fourteen days plus a test dose. You will take&#xD;
      the test dose in the clinic in the presence of the research nurse, and begin taking capsules&#xD;
      5 days before surgery (Day -5) for 5 days. If atorvastatin was found to be the more effective&#xD;
      drug in Part 1, you will take 1 unmarked capsule in the morning each day. If fish oil was&#xD;
      found to be the more effective drug in Part 1, you will take 3 capsules 2 times each day (a&#xD;
      total of 6 unmarked capsules each day). The capsules should be taken with a cup (8 ounces) of&#xD;
      water and may be taken with or without food.&#xD;
&#xD;
      You will be reminded by the research nurse to bring the remaining capsules from home prior to&#xD;
      admission for surgery.&#xD;
&#xD;
        -  If you are in Group 1, the capsules you will take will be the drug that was found to be&#xD;
           more effective in Part 1 (either fish oil supplements or atorvastatin).&#xD;
&#xD;
        -  If you are in Group 2, the capsules you will take will be placebo only.&#xD;
&#xD;
      You will have an equal chance of being assigned to each group. Neither you nor the study&#xD;
      staff will know if you are receiving the study drug or the placebo. However, if needed for&#xD;
      your safety, the study staff will be able to find out what you are receiving.&#xD;
&#xD;
      Surgery:&#xD;
&#xD;
      After you have taken the study drug/placebo for 5 days, you will have standard of care lung&#xD;
      surgery performed. You will be given a separate consent form to read and sign for the&#xD;
      surgery.&#xD;
&#xD;
      On the day of surgery, any unused capsules will be collected and the days, times, and reasons&#xD;
      why any doses were missed will be recorded. You will then continue taking the study&#xD;
      drug/placebo for up to 9 days after surgery or until you are released from the hospital&#xD;
      (whichever comes first). You will follow the same dosing schedule you followed before&#xD;
      surgery.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      Each day while you are in the hospital, your vital signs will be measured and you will be&#xD;
      checked for any allergic reaction you may have had to the study drug/placebo.&#xD;
&#xD;
      On Days 1 and 3, and on the last day that you take the study drug/placebo, blood (about 1&#xD;
      teaspoon) will be drawn to check your liver function.&#xD;
&#xD;
      About 4-6 weeks after surgery, you will have a follow-up visit. At this visit, the following&#xD;
      tests and procedures will be performed:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your vital signs.&#xD;
&#xD;
        -  You will be asked about any symptoms and/or side effects you may have had.&#xD;
&#xD;
        -  Blood (about 1 teaspoon) will be drawn to check your liver function.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will take the study drug/placebo for 5 days before surgery, and for up to 9 days after&#xD;
      surgery (up to a total of 14 days). Your participation in the study will be over after the&#xD;
      follow-up visit. You will be taken off study early if you have intolerable side effects (such&#xD;
      as allergic reaction or abnormal liver function tests).&#xD;
&#xD;
      This is an investigational study.&#xD;
&#xD;
      Up to 252 participants will take part in this study. All will be enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to low accrual.&#xD;
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidences of Atrial Fibrillation During First 4 Days After Lung Resection</measure>
    <time_frame>Baseline to 4 days post surgery</time_frame>
    <description>New onset of sustained (15 min or &gt;) or clinically significant (requiring intervention) atrial fibrillation (AF) during first 4 days post surgery as defined by on American College of Cardiology and American Heart Association Physician Consortium.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Advanced Cancers</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Atorvastatin capsule daily plus 3 Placebo capsules twice a day orally, 5 days pre-surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish Oil Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 Fish Oil capsules twice a day plus 1 Placebo capsule daily orally 5 days pre-surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 capsules orally every morning and 3 every evening for 5 days pre-surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>1 capsule by mouth every morning 5 days before surgery, and 9 days after surgery or until discharge.</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil Supplement</intervention_name>
    <description>3 capsules by mouth in the morning and evening 5 days before surgery, and 9 days after surgery or until discharge.</description>
    <arm_group_label>Fish Oil Supplement</arm_group_label>
    <other_name>n-3 PUFA</other_name>
    <other_name>Fish oil supplementation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.&#xD;
Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.&#xD;
Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge.</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_label>Fish Oil Supplement</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients need to be in a normal sinus rhythm preoperatively.&#xD;
&#xD;
          2. Participants undergoing planned lobectomy and 60 years of age or older or participants&#xD;
             undergoing planned pneumonectomy and 18 years of age or older.&#xD;
&#xD;
          3. Planned procedure is 5 days after the start of taking study drugs.&#xD;
&#xD;
          4. Signed written informed consent&#xD;
&#xD;
          5. Women of childbearing potential must have a negative pregnancy test (A woman of&#xD;
             childbearing potential is a women who has not been naturally postmenopausal for at&#xD;
             least 12 consecutive months or who has not undergone previous surgical sterilization)&#xD;
&#xD;
          6. Adequate liver function evidenced by; aspartate aminotransferase (AST or SGOT) &lt;/= 2.5&#xD;
             * Upper Limits of Normal (ULN), and alanine aminotransferase (ALT or SGPT) &lt;/= 2.5 *&#xD;
             ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any history of supraventricular arrhythmia for which the patient is taking&#xD;
             medications.&#xD;
&#xD;
          2. Current use of antiarrhythmic medications other than beta-receptor antagonists,&#xD;
             calcium-channel antagonists, or digitalis.&#xD;
&#xD;
          3. Use of any supplemental n-3 fatty acids during the previous three months.&#xD;
&#xD;
          4. Use of any statin therapy during the previous three months.&#xD;
&#xD;
          5. Patients known to have a history of recent drug or alcohol abuse.&#xD;
&#xD;
          6. Known allergy to seafood&#xD;
&#xD;
          7. Current use of Gemfibrozil and Fenofibrate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ara Vaporciyan, MD, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 10, 2010</study_first_submitted>
  <study_first_submitted_qc>December 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2010</study_first_posted>
  <results_first_submitted>April 24, 2012</results_first_submitted>
  <results_first_submitted_qc>June 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 1, 2012</results_first_posted>
  <last_update_submitted>July 31, 2012</last_update_submitted>
  <last_update_submitted_qc>July 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Genitourinary cancer</keyword>
  <keyword>Head and neck cancers</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Lipitor</keyword>
  <keyword>Fish Oil supplement</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: January 06, 2011 to July 29, 2011. All recruitment done at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>The study was terminated with only 2 participants enrolled. The inability to find participants was predominantly due to current or recent use of statins or fish oils.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin</title>
          <description>1 Atorvastatin capsule daily plus 3 Placebo capsules twice a day orally, 5 days pre-surgery.</description>
        </group>
        <group group_id="P2">
          <title>Fish Oil Supplement</title>
          <description>3 Fish Oil capsules twice a day plus 1 Placebo capsule daily orally 5 days pre-surgery.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>4 capsules orally every morning and 3 every evening for 5 days pre-surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Termination</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin</title>
          <description>1 Atorvastatin capsule daily plus 3 Placebo capsules twice a day orally, 5 days pre-surgery.</description>
        </group>
        <group group_id="B2">
          <title>Fish Oil Supplement</title>
          <description>3 Fish Oil capsules twice a day plus 1 Placebo capsule daily orally 5 days pre-surgery.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>4 capsules orally every morning and 3 every evening for 5 days pre-surgery.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="68" upper_limit="70"/>
                    <measurement group_id="B4" value="69" lower_limit="68" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidences of Atrial Fibrillation During First 4 Days After Lung Resection</title>
        <description>New onset of sustained (15 min or &gt;) or clinically significant (requiring intervention) atrial fibrillation (AF) during first 4 days post surgery as defined by on American College of Cardiology and American Heart Association Physician Consortium.</description>
        <time_frame>Baseline to 4 days post surgery</time_frame>
        <population>Analysis was to be per protocol. There is no analysis due to an inadequate number of enrolled participants in study which resulted in early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>1 Atorvastatin capsule daily plus 3 Placebo capsules twice a day orally, 5 days pre-surgery.</description>
          </group>
          <group group_id="O2">
            <title>Fish Oil Supplement</title>
            <description>3 Fish Oil capsules twice a day plus 1 Placebo capsule daily orally 5 days pre-surgery.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>4 capsules orally every morning and 3 every evening for 5 days pre-surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidences of Atrial Fibrillation During First 4 Days After Lung Resection</title>
          <description>New onset of sustained (15 min or &gt;) or clinically significant (requiring intervention) atrial fibrillation (AF) during first 4 days post surgery as defined by on American College of Cardiology and American Heart Association Physician Consortium.</description>
          <population>Analysis was to be per protocol. There is no analysis due to an inadequate number of enrolled participants in study which resulted in early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin</title>
          <description>1 Atorvastatin capsule daily plus 3 Placebo capsules twice a day orally, 5 days pre-surgery.</description>
        </group>
        <group group_id="E2">
          <title>Fish Oil Supplement</title>
          <description>3 Fish Oil capsules twice a day plus 1 Placebo capsule daily orally 5 days pre-surgery.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>4 capsules orally every morning and 3 every evening for 5 days pre-surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>decreased hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ara Vaporciyan, MD, BS / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

